Extended Half-Life (EHL) Recombinant Factor VIII
Treatment used for 1 condition
Total Trials
2
Total Participants
8K
Avg Effectiveness
90%
Avg Safety Score
65%
Conditions Treated
Click on a condition to view detailed treatment information and clinical trial data.